NASDAQ:CTOR Citius Oncology 5/14/2025 Earnings Report $1.53 -0.07 (-4.38%) Closing price 04:00 PM EasternExtended Trading$1.54 +0.01 (+0.92%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Citius Oncology EPS ResultsActual EPS-$0.11Consensus EPS -$0.09Beat/MissMissed by -$0.02One Year Ago EPSN/ACitius Oncology Revenue ResultsActual RevenueN/AExpected Revenue$5.74 millionBeat/MissN/AYoY Revenue GrowthN/ACitius Oncology Announcement DetailsQuarterDate5/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Citius Oncology Earnings HeadlinesCitius Oncology Announces Closing of $9.0 Million Public OfferingJuly 17 at 4:30 PM | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Public OfferingJuly 16 at 9:15 AM | prnewswire.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 18 at 2:00 AM | Porter & Company (Ad)Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution NetworkJuly 15 at 9:11 PM | msn.comCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraJuly 15 at 8:32 AM | prnewswire.comCitius Oncology launches $15M equity and warrant offering; shares downJuly 15 at 6:34 AM | msn.comSee More Citius Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email. Email Address About Citius OncologyCitius Oncology (NASDAQ:CTOR) (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted cancer therapies. Established as a spin-out from Citius Pharmaceuticals in 2021, the firm leverages proprietary DNA-based therapeutic platforms to create novel oncology agents. Its mission is to address critical unmet needs in solid tumors by advancing candidates that combine precise tumor targeting with innovative mechanisms of action. The company’s pipeline comprises multiple clinical-stage programs, including a DNA-intercalating small molecule designed to induce tumor cell death, a novel chlorotoxin-derived targeting peptide conjugate aimed at selectively binding and penetrating malignant tissue, and an immune-modulating biologic that activates innate pathways to enhance antitumor responses. These candidates are being evaluated across indications such as glioblastoma, pancreatic cancer and hepatic metastases. In addition to in-house research and development, Citius Oncology engages in strategic partnerships with academic institutions and contract development organizations to accelerate preclinical and clinical studies. The company has established scalable manufacturing processes compliant with current Good Manufacturing Practices (cGMP) and is pursuing regional collaborations to support regulatory filings and market access in North America and Europe. The leadership team brings extensive experience from major pharmaceutical and biotechnology companies, with expertise spanning oncology research, clinical development, manufacturing and regulatory affairs. Supported by a scientific advisory board of oncologists and translational researchers, the management team is focused on advancing its pipeline through key clinical milestones and preparing for eventual commercialization.Written by Jeffrey Neal JohnsonView Citius Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
